Lilly trades at a premium to Ozempic-maker Novo as obesity drugs boom
Deutsche Bank analyst James Shin says there are several reasons why Lilly should trade at a premium to Novo Nordisk.
Source: cnbc.com
Stay updated with breaking news from Does Eli Lilly. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Deutsche Bank analyst James Shin says there are several reasons why Lilly should trade at a premium to Novo Nordisk.
This pharmaceutical giant has proved to be a tremendous wealth creator for its shareholders in recent years.